Skip to main content

Advertisement

SpringerLink
Log in

Propensity score matched lesion-based comparison of long-term clinical and angiographic outcomes after placement of sirolimus (Cypher Bx Velocity) and paclitaxel (TAXUS Express)-eluting stents for de novo native coronary stenosis

  • Original Article
  • Published:
Cardiovascular Intervention and Therapeutics Aims and scope Submit manuscript

Abstract

Long-term clinical and angiographic outcomes after sirolimus (SES: Cypher Bx Velocity) and paclitaxel (PES: TAXUS Express)-eluting stent implantation were firstly compared in Japan. During PES-available period from May 2007 to February 2009, 1068 nonrandomized consecutive de novo native coronary lesions treated either with a PES (682 lesions) or SES were enrolled in this study, and a retrospective examination was conducted in April 2013. During that interval, the use ratio of drug-eluting stent (i.e. SES plus PES) was 94.2 %. By adjusting the baselines with a propensity score matching analysis produced 383 lesions in each arm, the incidence of the clinical endpoint (1500-day cardiac death, nonfatal recurrent myocardial infarction, and definite stent thrombosis) after placement of SES (2.1 %; mean follow-up, 1400 ± 290 days) was not significantly different from that in the PES group (2.6 %; 1394 ± 325 days, p = 0.637). SES did not relate to the clinical endpoint (hazard ratio 1.04; 95 % CI 0.29–3.76; p = 0.949). In the baseline-adjusted angiographic followed up lesions (n = 234 in each arm), the incidence of binary restenosis (percent diameter stenosis [%DS] >50 %) in the SES group (12.0 %; mean follow-up, 477 ± 281 days) was not significantly different from that in the PES group (14.5 %; 497 ± 341 days, p = 0.431). SES did not relate to binary restenosis (Odds ratio 0.73; 95 % CI 0.40–1.32; p = 0.295). In conclusion, the present propensity score matched lesion-based analysis firstly showed the statistical equivalent long-term clinical and angiographic outcomes after either SES or PES placement for de novo native coronary lesion in Japanese patients in a daily practice environment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fukumoto A, Otsuji S, Takiuchi S, Ikushima M, Asano K, Terasoma K, et al. Comparison of real-world clinical outcomes between Cypher- and Taxus-eluting stents: the GARA–GARA study. Cardiovasc Interv Ther. 2011;26:202–8.

    Article  PubMed  CAS  Google Scholar 

  2. Ishikawa T, Nakano Y, Mutoh M. Retrospective comparison of midterm clinical and angiographic outcomes after the implantation of paclitaxel- and sirolimus-eluting stents for de novo coronary complex lesions in nonrandomized Japanese patients. Intern Med. 2012;51:2695–701.

    Article  PubMed  CAS  Google Scholar 

  3. Ishikawa T, Mutoh M, Nakano Y, Suzuki T, Nakata K, Murakami A, et al. Post-discharge clinical and angiographic outcomes of patients presenting within 48 hours of STEMI treated with paclitaxel- or sirolimus-eluting stents. J Cardiol. 2012;60:174–9.

    Article  PubMed  Google Scholar 

  4. Tsujita H, Hamazaki Y, Nishikura T, Yokota H, Kondo S, Hosokawa S, et al. Sirolimus-eluting stents versus paclitaxel-eluting stents for coronary intervention in patients with renal failure on hemodialysis. Cardiovasc Interv Ther. 2013;28:9–15.

    Article  PubMed  CAS  Google Scholar 

  5. Mutoh M, Ishikawa T, Hasuda T, Okada H, Endo A, Miyanaga S, et al. Predictors of target lesion revascularization and documented stent thrombosis beyond 30 days after sirolimus-eluting stent implantation-retrospective analysis in consecutive 1070 angiographic follow-up lesions. Circ J. 2007;71:1328–31.

    Article  PubMed  Google Scholar 

  6. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119:987–95.

    Google Scholar 

  7. Ishikawa T, Nakano Y, Endoh A, Kubota T, Suzuki T, Nakata K, et al. Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies. J Cardiol. 2009;54:238–44.

    Article  PubMed  Google Scholar 

  8. Kubota T, Ishikawa T, Mutoh M. Retrospective comparison of the clinical and angiographic outcomes of the sirolimus-eluting stent and the bare-metal stent in 2031 nonrandomized consecutive de novo native coronary lesions. Intern Med. 2011;50:2463–70.

    Article  PubMed  Google Scholar 

  9. Ishikawa T, Mutoh M, Nakano Y, Endoh A, Kubota T, Suzuki T, et al. Retrospective comparison of clinical and angiographic outcomes after primary stenting using sirolimus-eluting and bare-metal stents in nonrandomized consecutive 568 patients with first ST-segment elevated myocardial infarctions. J Cardiol. 2011;57:44–52.

    Article  PubMed  Google Scholar 

  10. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al; on Behalf of the j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012;125:584–91.

    Google Scholar 

  11. Kotani J, Ikari Y, Kyo E, Nakamura M, Yokoi H, Furuno K, et al. Five-year outcomes of Cypher™ coronary stent: report from J-PMS Study. Cardiovasc Interv Ther. 2012;27:63–71.

    Article  PubMed  Google Scholar 

  12. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–51.

    Google Scholar 

  13. Moliterno DJ. Healing Achilles–sirolimus versus paclitaxel. N Engl J Med. 2005;353:724–7.

    Article  PubMed  CAS  Google Scholar 

  14. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation. Analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1193–200.

    Article  PubMed  Google Scholar 

  15. Ishikawa T, Nakano Y, Hino S, Suzuki T, Murakami A, Tsutsumi J, et al. Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Liberté stents for de novo native coronary stenosis. J Cardiol. 2013. [Epub ahead of print].

  16. Kubota T, Ishikawa T, Nakano Y, Endoh A, Suzuki T, Sakamoto H, et al. Retrospective comparison of clinical and angiographic outcomes after sirolimus-eluting and bare-metal stents implantation for nonrandomized consecutive 312 severe calcified lesions using rotablator. Int Heart J. 2011;52:65–71.

    Article  PubMed  Google Scholar 

  17. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872–8.

    Article  PubMed  CAS  Google Scholar 

  18. Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819–28.

    Article  PubMed  CAS  Google Scholar 

  19. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al; REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895–904.

    Google Scholar 

  20. Galløe AM, Thuesen L, Kelbæk H, Thayssen P, Rasmussen K, Hansen PR, et al; SORT OUT II Investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice. JAMA 2008;299:409–16.

    Google Scholar 

  21. Mayor M, Malik AZ, Minor RJ Jr, Deshpande MC, Strauss WE, Maloney TH, et al. One-year outcomes from the TAXUS express stent versus cypher stent. Am J Cardiol. 2009;103:930–6.

    Article  PubMed  Google Scholar 

  22. Agostoni P, Cosgrave J, Biondi-Zoccai GG, Sangiorgi GM, Ge L, Melzi G, et al. Angiographic analysis of pattern of late luminal loss in sirolimus- and paclitaxel-eluting stents. Am J Cardiol. 2007;99:593–8.

    Article  PubMed  CAS  Google Scholar 

  23. Park CB, Hong MK, Kim YH, Park DW, Han KH, Lee CW, et al. Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent. Int J Cardiol. 2007;120:387–90 [Epub 2007 Feb 8].

    Article  PubMed  Google Scholar 

  24. Solinas E, Dangas G, Kirtane AJ, Lansky AJ, Franklin-Bond T, Boland P, et al. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol. 2008;102:311–5. doi:10.1016/j.amjcard.2008.03.060 [Epub 2008 May 24].

    Article  PubMed  CAS  Google Scholar 

  25. Gao Z, Yang Y, Xu B, Chen J, Qiao S, Li J, et al. Three year follow-up of the sirolimus-eluting stent and the paclitaxel-eluting stent in daily practice. Clin Cardiol. 2009;32:E63–7. doi:10.1002/clc.20550.

    Article  PubMed  Google Scholar 

  26. Kimura T, Isshiki T, Hayashi Y, Oshima S, Namura M, Nakashima H, et al. Incidence and outcome of surgical procedures after sirolimus-eluting stent implantation: a report from the j-Cypher registry. Cardiovasc Interv Ther. 2010;25:29–39.

    Article  PubMed  Google Scholar 

  27. Endo A, Ishikawa T, Suzuki T, Kashiwagi Y, Mutoh M. Direct microscopic observation of striations in a fractured section of a sirolimus-eluting stent (Cypher Bx Velocity®) indicates induction of stent fracture by continuous shear stress. Int Heart J. 2011;52:248–51.

    Article  PubMed  Google Scholar 

  28. Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123:2382–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None declared.

Author information

Authors and Affiliations

  1. Division of Cardiology, Saitama Cardiovascular Respiratory Center, 1696 Itai, Kumagaya, Saitama, 360-0197, Japan

    Yosuke Nakano, Tetsuya Ishikawa & Makoto Mutoh

  2. Division of Neuropsychiatry, Ishikawa Prefectural Takamatsu Hospital, Kanazawa, Japan

    Shoryoku Hino

Authors
  1. Yosuke Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shoryoku Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Mutoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsuya Ishikawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakano, Y., Ishikawa, T., Hino, S. et al. Propensity score matched lesion-based comparison of long-term clinical and angiographic outcomes after placement of sirolimus (Cypher Bx Velocity) and paclitaxel (TAXUS Express)-eluting stents for de novo native coronary stenosis. Cardiovasc Interv and Ther 29, 93–101 (2014). https://doi.org/10.1007/s12928-013-0215-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12928-013-0215-7

Keywords

Search

Navigation